Phase I Testing of a Malaria Vaccine Composed of Hepatitis B Virus Core Particles Expressing Plasmodium falciparum Circumsporozoite Epitopes

We report the first phase I trial to assess the safety and immunogenicity of a malaria vaccine candidate, ICC-1132 (Malarivax), composed of a modified hepatitis B virus core protein (HBc) containing minimal epitopes of the Plasmodium falciparum circumsporozoite (CS) protein. When expressed in Escher...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Nardin, Elizabeth H., Oliveira, Giane A., Calvo-Calle, J. Mauricio, Wetzel, Kristiane, Maier, Carolin, Birkett, Ashley J., Sarpotdar, Pramod, Corado, Michael L., Thornton, George B., Schmidt, Annette
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society for Microbiology 2004
Aiheet:
Microbial Immunity and Vaccines
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC523031/
https://ncbi.nlm.nih.gov/pubmed/15501783
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/IAI.72.11.6519-6527.2004
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia